Regulatory FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy Pharmaceutical TechnologyAstraZeneca has secured FDA approval for Imfinzi in combination with BCG induction and maintenance therapy for adults with BCG-nave, high-risk NMIBC.OncologyRead full story pharminent June 1, 2026 (Last updated: June 1, 2026) Pharmaceutical Technology AstraZeneca has secured FDA approval for Imfinzi in combination with BCG induction and maintenance therapy for adults with BCG-nave, high-risk NMIBC. Oncology Read full story Post navigation Previous: Previous PostNext: Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026